医生-我应该接种 COVID-19 疫苗吗？神经肌肉疾病个体的感染与免疫
Doctor-Should I get the COVID-19 vaccine? Infection and immunization in individuals with neuromuscular disorders.
机构信息
Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Department of Neurology, Stritch School of Medicine, Loyola University, Chicago, Illinois, USA.
出版信息
Muscle Nerve. 2021 Mar;63(3):294-303. doi: 10.1002/mus.27179. Epub 2021 Jan 27.
Abstract
The clinical course of neuromuscular disorders (NMDs) can be affected by infections, both in immunocompetent individuals, and in those with reduced immunocompetence due to immunosuppressive/immunomodulating therapies. Infections and immunizations may also trigger NMDs. There is a potential for reduced efficacy of immunizations in patients with reduced immunocompetence. The recent vaccination program for coronavirus disease-2019 (COVID-19) raises several questions regarding the safety and efficacy of this vaccine in individuals with NMDs. In this Practice Topic article, we address the role of vaccine-preventable infections in NMDs and the safety and efficacy of immunization in individuals with NMDs, with emphasis on vaccination against COVID-19.
摘要
神经肌肉疾病（NMDs）的临床病程可能受到感染的影响，无论是在免疫功能正常的个体中，还是在因免疫抑制/免疫调节治疗而免疫功能降低的个体中。感染和免疫接种也可能引发 NMDs。免疫功能降低的患者免疫接种的效果可能会降低。最近针对 2019 年冠状病毒病（COVID-19）的疫苗接种计划提出了一些关于该疫苗在 NMD 患者中的安全性和有效性的问题。在这篇实践专题文章中，我们讨论了可通过疫苗预防的感染在 NMD 中的作用，以及 NMD 患者免疫接种的安全性和有效性，重点是针对 COVID-19 的疫苗接种。
相似文献
1
Doctor-Should I get the COVID-19 vaccine? Infection and immunization in individuals with neuromuscular disorders.
Muscle Nerve. 2021 Mar;63(3):294-303. doi: 10.1002/mus.27179. Epub 2021 Jan 27.
2
COVID-19 and neuromuscular disorders.
Neurology. 2020 Jun 2;94(22):959-969. doi: 10.1212/WNL.0000000000009566. Epub 2020 Apr 13.
3
Neuromuscular diseases associated with COVID-19 vaccines: a systematic review and pooled analysis of 258 patients.
BMC Neurol. 2023 Dec 11;23(1):437. doi: 10.1186/s12883-023-03486-y.
4
Guillain-Barré syndrome in an era of global infections and 21st century vaccination.
Curr Opin Neurol. 2022 Oct 1;35(5):571-578. doi: 10.1097/WCO.0000000000001086. Epub 2022 Jul 18.
5
Vaccination recommendations for patients with neuromuscular disease.
Vaccine. 2014 Oct 14;32(45):5893-900. doi: 10.1016/j.vaccine.2014.09.003. Epub 2014 Sep 16.
6
Hesitancy, reactogenicity and immunogenicity of the mRNA and whole-virus inactivated Covid-19 vaccines in pediatric neuromuscular diseases.
Hum Vaccin Immunother. 2023 Dec 31;19(1):2206278. doi: 10.1080/21645515.2023.2206278. Epub 2023 May 9.
7
Guillain-Barré Syndrome Associated with COVID-19 Vaccination.
Emerg Infect Dis. 2022 May;28(5):1079-1080. doi: 10.3201/eid2805.212145.
8
Association Between Guillain-Barré Syndrome and COVID-19 Infection and Vaccination: A Population-Based Nested Case-Control Study.
Neurology. 2023 Nov 14;101(20):e2035-e2042. doi: 10.1212/WNL.0000000000207900. Epub 2023 Oct 18.
9
Uptake, effectiveness and safety of COVID-19 vaccines in individuals at clinical risk due to immunosuppressive drug therapy or transplantation procedures: a population-based cohort study in England.
BMC Med. 2024 Jun 10;22(1):237. doi: 10.1186/s12916-024-03457-1.
10
Guillain-Barre syndrome should be monitored upon mass vaccination against SARS-CoV-2.
Hum Vaccin Immunother. 2021 Sep 2;17(9):2957-2958. doi: 10.1080/21645515.2021.1922061. Epub 2021 May 25.
引用本文的文献
1
Immunoinformatic-driven design and evaluation of multi-epitope mRNA vaccine targeting HIV-1 gp120.
Front Immunol. 2025 May 13;16:1480025. doi: 10.3389/fimmu.2025.1480025. eCollection 2025.
2
Evaluation of Clinical Effects of COVID-19 Infection and Vaccines on Myasthenia Gravis.
Noro Psikiyatr Ars. 2024 Aug 19;67(3):213-220. doi: 10.29399/npa.28418. eCollection 2024.
3
Hesitancy, reactogenicity and immunogenicity of the mRNA and whole-virus inactivated Covid-19 vaccines in pediatric neuromuscular diseases.
Hum Vaccin Immunother. 2023 Dec 31;19(1):2206278. doi: 10.1080/21645515.2023.2206278. Epub 2023 May 9.
4
Exacerbation of Pre-existing Neurological Symptoms With COVID-19 in Patients With Chronic Neurological Diseases: An Updated Systematic Review.
Cureus. 2022 Sep 18;14(9):e29297. doi: 10.7759/cureus.29297. eCollection 2022 Sep.
5
Early immunological responses to the mRNA SARS-CoV-2 vaccine in patients with neuromuscular disorders.
Front Immunol. 2022 Sep 29;13:996134. doi: 10.3389/fimmu.2022.996134. eCollection 2022.
6
The relationship between myasthenia gravis and COVID-19: a systematic review.
Egypt J Neurol Psychiatr Neurosurg. 2022;58(1):83. doi: 10.1186/s41983-022-00516-3. Epub 2022 Jul 7.
7
Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: Data from an Italian Cohort.
Neurol Int. 2022 Apr 27;14(2):406-416. doi: 10.3390/neurolint14020033.
8
Neuromuscular complications after COVID-19 vaccination: a series of eight patients.
Acta Neurol Belg. 2022 Jun;122(3):753-761. doi: 10.1007/s13760-022-01941-0. Epub 2022 May 2.
9
Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience.
Eur J Neurol. 2022 Aug;29(8):2505-2510. doi: 10.1111/ene.15348. Epub 2022 Apr 17.
10
Vaccination and immunotherapies in neuroimmunological diseases.
Nat Rev Neurol. 2022 May;18(5):289-306. doi: 10.1038/s41582-022-00646-5. Epub 2022 Apr 6.
本文引用的文献
1
Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.
MMWR Recomm Rep. 2020 Sep 25;69(9):1-41. doi: 10.15585/mmwr.rr6909a1.
2
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
3
Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection.
Adv Drug Deliv Rev. 2021 Feb;169:168-189. doi: 10.1016/j.addr.2020.12.006. Epub 2020 Dec 13.
4
The Advisory Committee on Immunization Practices' Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine - United States, 2020.
MMWR Morb Mortal Wkly Rep. 2020 Dec 11;69(49):1857-1859. doi: 10.15585/mmwr.mm6949e1.
5
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
6
Incidence, clinical, risk factors and outcomes of Guillain-Barré in Covid-19.
Ann Neurol. 2021 Mar;89(3):598-603. doi: 10.1002/ana.25987. Epub 2020 Dec 28.
7
Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases.
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):319-327. doi: 10.1182/hematology.2020000116.
8
Nerve Compression Injuries After Prolonged Prone Position Ventilation in Patients With SARS-CoV-2: A Case Series.
Arch Phys Med Rehabil. 2021 Mar;102(3):359-362. doi: 10.1016/j.apmr.2020.10.131. Epub 2020 Nov 25.
9
Mononeuritis multiplex: an unexpectedly frequent feature of severe COVID-19.
J Neurol. 2021 Aug;268(8):2685-2689. doi: 10.1007/s00415-020-10321-8. Epub 2020 Nov 26.
10
The Advisory Committee on Immunization Practices' Ethical Principles for Allocating Initial Supplies of COVID-19 Vaccine - United States, 2020.
MMWR Morb Mortal Wkly Rep. 2020 Nov 27;69(47):1782-1786. doi: 10.15585/mmwr.mm6947e3.
Zotero 插件